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RADIATION DOSE TO VETERINARIANS AND VETERINARY TECHNICIANS DURING 
PERFORMANCE OF RADIOIODINE TREATMENT OF FELIS CATUS 
 
 
The purpose of this project is to determine I-131 uptake of veterinarians or veterinary 
staff when radioiodine (I-131) is administered via injection to domesticated cats (Felis catus) 
with hyperthyroidism. Currently, veterinarians and staff perform a bioassay either every three 
months or if they have administered a cumulative 10 mCi of I-131. Veterinarians and staff 
undergo specific training for the handling of radioiodine injection of cats to minimize and 
prevent an intake. A bioassay is performed post cat injection to determine if I-131 was inhaled or 
absorbed. The frequency of these bioassays requires dedicated time of the veterinarians and those 
who must perform the bioassay. Bioassay data from veterinarians and staff at the Colorado State 
University Veterinary Teaching Hospital (CSU VTH) administering I-131 from the past 20 years 
were analyzed to ascertain if there is a correlation between the amount of time elapsed between 
the I-131 administration and the bioassay and the net counts resulting from the bioassay. The  
amount of I-131 administration and the bioassay net counts were also analyzed to determine if 
there was a correlation. No correlations were found, and out of 168 I-131 administrations over 20 
years, only 7 bioassays showed measurable doses of I-131 of a committed dose equivalent 
(CDE) of 5.71 mrem (n=1), 7.53 mrem (n=2), 10.9 mrem (n=1), 20.7 mrem (n=1), and 75.1 
mrem (n=2). The current precautions taken to prevent the intake of I-131 appear sufficient 
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Thyroid Hormones and Thyroid Tumors in Cats 
The thyroid is necessary for the regulation of metabolism in the body and is dependent on 
a source of iodine to function properly. Domesticated cats (Felis catus) are unable to produce 
iodine themselves, so they obtain it from food rich in iodine (Chung 2014). Two of the hormones 
the thyroid produces are reliant on iodine for their creation: the “thyroid hormones”, 
triiodothyronine (T3) and tetraiodothyronine (T4). The level of hormones in the bloodstream is 
regulated by signals from the pituitary gland, signaling the thyroid gland to release either more or 
less hormones. T3 and T4, which increase the basal metabolic rate, are reliant on the supply of 
iodine in order to be created, thus causing iodine to accumulate in the thyroid in greater 
quantities than elsewhere in the body (IQWiG 2018).  
Domesticated cats are prone to developing thyroid adenomas or carcinomas as they age. 
The cancerous cells in the thyroid can cause hyperthyroidism, a condition in which the thyroid 
produces too much T3 and T4. Signs of a cat with hyperthyroidism can include weight loss, 
anorexia, hyperactivity, and an abnormal coat (Barber 2007). Veterinarians can conduct 
bloodwork, urinalysis, and other biochemical analyses, such as checking for azotemia and 
hyperphosphatemia, on the cats to confirm if they have hyperthyroidism, thus indicating that 
they may have a thyroid adenoma or carcinoma (Mooney 2001). Another common issue with 
thyroid tumors in cats is that there is a high risk of metastasis, causing concern that other tumors 
could develop elsewhere in the body (Barber 2007). 
 
Thyroid Tumors Treatment in Cats 
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When an adenoma or carcinoma forms in the thyroid, radioiodine (I-131) can be used to 
destroy the cells causing the tumor. Since radioiodine is chemically identical to stable iodine, the 
body retains and metabolizes all isotopes of iodine in the same way. While I-127, found naturally 
in food, is stable, I-131 undergoes beta decay. The complete decay scheme for I-131 is in 
Appendix A. Since hyperthyroidism, an indicator of the likely presence of a thyroid tumor, 
causes an increase in the production of T3 and T4, the thyroid will be using more iodine than 
when it is functioning properly, ensuring the uptake of the radioiodine by the thyroid (Mooney 
2001). Even if the tumor is not accompanied by hyperthyroidism, the thyroid will still uptake the 
I-131. In addition to the thyroid preferentially uptaking iodine, the most metabolically active 
tissues in the thyroid, the cancer cells, will uptake more iodine than the normal cells. 
The average amount of energy released by a beta particle in the decay of I-131 is 0.1916 
MeV1. The maximum range of the beta particle can be determined using Equation 5.3 from 
Introduction to Health Physics, 5th Edition. 
 
R = 0.404E1.38          (1) 
where 
R = range of the beta particle in g/cm2 
E = maximum energy of the beta particle in MeV 
 
The range of a beta particle from I-131 is approximately 0.411 g/cm2. The average mass 
of a normal cat’s thyroid is 350 mg (Cartee et al. 1993). Assuming tissue has the same density as 
 




water (1 g/cm3), the volume of the thyroid is 0.350 cm3, 0.04 cm is the approximate distance the 
beta particles will travel, so the bulk of I-131 emissions will be assumed to be absorbed in the 
thyroid. The average dimensions of a cat’s thyroid are 19.31 mm × 5.42 mm × 3.23 mm, so a 
beta particle deposited in the middle of the thyroid would not have sufficient energy to escape 
(Cartee et al. 1993). 
The energy deposited by the decay of I-131 is sufficient to cause single stranded breaks 
(SSBs) and double stranded breaks (DSBs) in the DNA of the cancerous and normal cells within 
the thyroid, though the normal cells outside the thyroid are spared because the majority of the 
dose from I-131 comes from beta decay. DNA is normally capable of repairing an SSB or DSB 
through homologous repair or non-homologous end joining. As the amount of SSBs and DSBs 
increase with the continued presence of I-131 in the thyroid, however, the DNA is less capable of 
keeping up with the repairs and ensuring their viability, especially if there is clustered damage, 
and thus induces cell death through apoptosis (Sage et al. 2017). The body is able to naturally 
replace the normal thyroid cells over time and normal thyroid function resumes. Radioiodine 
treatment is highly successful in cats and usually there is no need for a second administration 
(Barber 2007). 
I-131 can be delivered either subcutaneously or intravenously in doses of either 74 – 222 
MBq (2-6 mCi) for adenomas or 1.11 – 1.48 GBq (30-40 mCi) for carcinomas (HICON 1971). 
When radioiodine is taken into the human bloodstream, 70% of it travels directly to the urinary 
tract and is eliminated from the body within 7 days. The other 30% is uptaken by the thyroid, 
metabolized by the tissues, and converted into inorganic iodine. 20% of the inorganic iodine 
from the thyroid is eliminated in the feces, the other 80% is brought back into the bloodstream 
(ICRP 1989). Figure 1 shows the pathway that iodine takes when it enters the human body. 
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Figure 1: Movement of iodine through the body. 
Iodine is assumed to behave similarly in cats. The effective half-life of radioiodine is 
approximately 8 days in humans, and it is assumed to be similar in cats. The cat’s owner’s 
radiation dose is maintained as low as reasonably achievable (ALARA) by keeping the cat in the 
hospital for 96 hours (12 half lives) and releasing the cat when the measured exposure rate from 
30 cm (one foot) is no more than 0.129 µC/kg (0.5 mR/h), in accordance with the regulations 
Colorado State University (CSU) has from the Colorado Department of Public Health and the 

















Chemical Form of Administered Iodine-131 
The I-131 used is in a solution of sodium iodide from HICON™. The solution has 
carrier-free NaI with a radioconcentration of 1,000 mCi/mL, 2 mg of diosodium edetate 
dihydrate USP, 4.4 mg of sodium thiosulfate pentahydrate USP, and 40 mg of dibasic sodium 
phosphate anhydrous USP (HICON 1971). While it is possible that the iodine could become 
volatilized, thus becoming an inhalation hazard to the person performing the procedure, there 
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have been precautionary measures taken to ensure that volatilization is unlikely. There are 
specific conditions that the I-131 solution must have in order to become volatilized. According to 
the safety data sheet (SDS), the I-131 has a low reactivity and will remain stable while stored in 
a dry, dark, cool, and ventilated area (Jubilant DraxImage 2017). If it is mixed with an acid or 
heated there may be a release of gaseous I-131. In order for the iodine to become volatile, the 
iodine ion (I-) must first become oxidized from the sodium iodide and form I2. Potential 
oxidation is slowed by storing the I-131 solution in a dark, cool place. The sodium thiosulfate 
pentahydrate in the solution acts as a reducing agent, preventing any potential volatilization of 
the iodine through oxidation (Hung 1997).  
 
CSU Procedures for Iodine-131 Administration 
Colorado State University’s (CSU) James L. Voss Veterinary Teaching Hospital (VTH) 
offers thyroid cancer treatment for domesticated cats. The administering person is required to 
wear personal protective equipment (PPE), which includes gloves, eye protection, a surgical 
mask, a lab coat, pants, and close-toed shoes2.   
 
Sodium Iodide (NaI(Tl)) Detector 
 
 I-131 in the thyroid can be detected using a scintillation counter, most commonly a 
sodium iodide crystal with thallium “impurities” (NaI(Tl)) to act as an activator. I-131 emits a 
364 keV gamma ray with an abundance of approximately 81% that can be detected outside the 
human body and with an NaI detector (NCHPS 2006). Within the structure of the crystal there 
are two discrete energy bands: the conduction band and the valence band. The two bands are 
 
2 From correspondence with RSO Jim Abraham. 
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separated by the forbidden gap. Electrons bound to the crystal are typically present in the valence 
band, the lower of the two. When a gamma ray interacts with the atoms of the crystal, its kinetic 
energy causes the electrons to become excited and ionized. As the electrons become excited, they 
jump from the valence band to the conduction band, leaving a hole where it left. The electron-
hole pair will rejoin through the electron in the conduction band releasing a certain quantum of 
light to fall back to the valence band. The light is sensed by the cathode of a photomultiplier tube 
within the detector. Electrons are removed from the cathode and travel to a dynode. As these 
original electrons strike the dynode, which is a second cathode with a higher positive voltage, 
additional electrons are removed from the dynode. The accumulation of electrons travels to the 
next dynode, and the process continues for a total of about ten times, thus ultimately increasing 
the number of electrons proportionally to the amount of energy deposited by the gamma ray 
originally. The output pulse is then detected (Johnson 2017).  
  
Bioassay of Iodine-131 Administering Personnel 
A background count is always conducted before any bioassays.  In order to conduct a 
background count, an anthropomorphic phantom is placed under the NaI(Tl) detector. The 
detector used at CSU is the Captus 3000 (Capintec, Inc. 2010). The materials used in the 
phantoms have a density that is tissue-equivalent so that radiation will interact with it in the same 
way it would with normal tissue (Ramos et al. 2017). The specific phantom used at CSU is the 
Mirion Technologies CAPTUS Neck Phantom, which is made of polymethyl methacralate 
(Lucite)3. Lucite has a density of 1.19 g/cm3 4, which is comparable to that of soft tissue (1 
 
3 https://capintec.com/product/neck-phantom/ Accessed 14 December 2020. 
 
4 https://physics.nist.gov/cgi-bin/Star/compos.pl?matno=223 Accessed 14 December 2020. 
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g/cm3). The background count of the room with the phantom in it allows for subtraction of 
radiation that is not due to the iodine administration, increasing the precision of the background 
count. Figure 2 shows the NaI(Tl) detector set up, and Figure 3 shows the phantom that is used to 
determine the background counts. 
 





















Prior to handling any I-131, the administering person must have a baseline bioassay 
performed. Under the radioactive materials license that CSU has from the CDPHE, all 
individuals who administer I-131 to cats and those who care for the cats post-administration must 
have bioassays performed within 24-72 hours of administration (CDPHE 2019). The regulations 
documented in the CDPHE guidelines are specifically written for the administering persons 
following the guidelines from NRC Regulatory Guide 8.20. Regulatory Guide 8.20 states that 
bioassays are necessary for people who work with a cumulative amount of at least 370 MBq (10 
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mCi) of I-131 over a three-month period when the I-131 is in a nonvolatile form when handled 
on a lab bench or in an open room. If at any point during the three-month period the cumulative 
amount is greater than 370 MBq (10 mCi), a bioassay must be conducted. Regulatory Guide 8.20 
also lists predetermined action levels (PALs). If the administering person’s thyroid contains 
more radioactivity than a PAL, further tests and investigations must be conducted. If the thyroid 
content exceeds 37 kBq (1 µCi), then an investigation is conducted, and measures must be taken 
to prevent any similar exposures.  A follow up in vivo bioassay must be conducted within 24 
hours of the first one, or an in vitro bioassay must be taken within two weeks of the first one. If 
the thyroid content exceeds 185 kBq (5 µCi), then a medical professional must be contacted 
within 2-3 hours so thyroid blocking can be evaluated and performed if necessary. Bioassay 
measurements at 1-week intervals must be taken until the thyroid content is less than 1 µCi 
(NRC 2014). If the dose to the vet or vet tech exceeds the whole body effective dose limit of 
0.05 Sv (5 rem), or organ dose limit of 0.5 Sv (50 rem), then their work would have to be 
restricted from additional dose (NRC 1991). 
 
Regulatory Limits for Iodine-131 
The nonstochastic annual limit of intake (NALI) is the limit at which the incorporation of 
a radionuclide to an organ will not reach the threshold of causing nonstochastic effects, such as 
tissue necrosis or radiation sickness. The inhalation NALI of I-131 is 50 µCi, which delivers an 
equivalent dose of 0.5 Sv (50 rem) to the thyroid (NRC 2018). Based on the current 
recommendations listed in Regulatory Guide 8.20, the administering person must have a 
bioassay performed if they have worked with a cumulative amount of 10 mCi of I-131 during a 
three-month (90 day) period (10 mCi, if inhaled, is the equivalent of 10 rems to the thyroid).  
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If the administering person reached 10% of the NALI, equivalent to an uptake of 1.67 
µCi (5 rems thyroid), the I-131 uptaken by the thyroid would still be detectable above 
background 55.8 days post-intake (using the CSU NaI(Tl) system), as shown in Appendix B. 
Regulatory Guide 8.20 states that “methods or solutions that differ from those described in this 
regulatory guide may be deemed acceptable if they provide sufficient basis and information for 
the NRC staff to verify that the proposed alternative demonstrates compliance with the 
appropriate NRC regulations”. The intake limit of 10 mCi currently set by the regulatory guide is 
20% of the NALI, meaning an uptake of 3.33 mCi of I-131, will be detectable using the CSU 
NaI(Tl) system for 138.6 days, as shown in Appendix C. 
A previous study involving the iodination of human patients indicated that any uptakes 
by technicians have been well below regulatory limits (Collier 2016). If all doses to patients are 
10% below the legal limits, individual monitoring of the administering person is not required by 
10 CFR 20.1502. 10 CFR 20.1502 also states that no monitoring is required if all intakes of the 
administering person are likely to be 10% below the legal limits.  
 
Costs Associated with Bioassay 
Every time a bioassay is performed, there is a loss in productivity, both for the radiation 
safety officer (RSO) and administering person. The commute approximately from the CSU VTH 
to the RSO is approximately 8 minutes if driving, 10 minutes if biking. Each administering 
person must wait to ensure the RSO is free to conduct the thyroid scan. The scan lasts for a 
minimum of 10 minutes, with 5 minutes to count the background and 5 minutes to count the 
person. Then there is the 8-10-minute commute back to the CSU VTH. The RSO must also 
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prepare paperwork for each bioassay prior and post analysis. Overall this whole process costs a 
minimum of 40 – 60 minutes of the workday for two people each time a bioassay is performed.  
Additionally, the failure to perform a bioassay would put the veterinary hospital and RSO 
in violation of written protocols, which could result in fines, or even a loss of radioactive 
materials licenses and the right to use radioactive materials.  
 
Purpose of Study 
The purpose of this study is to ascertain if a correlation exists between the amount of 
radioiodine administered to domesticated cats and iodine uptake in the thyroid of the 
administering person. Additionally, determination of evidence to decrease bioassay frequency 
will be examined. It is hypothesized that that there would be a negative correlation between the 
time elapsed and the net counts and a positive correlation between amount of I-131 administered 











 This project was determined exempt by the Colorado State University Institutional 
Review Board. The letter documenting the exemption can be found in Appendix D.  
Scans of 168 iodine bioassays from veterinarians and veterinary technicians who worked 
at the CSU VTH were de-identified by the RSO. The date of the radioiodine administration, 
amount of radioiodine administered (mCi), date of the bioassay, amount of time elapsed between 
administration and the bioassay (days), radioiodine background (cpm), net counts (cpm), and 
activity of the administering person’s thyroid (mCi) were recorded in an Excel spreadsheet.  
   
Z-score Calculation 
 A Z-score was calculated for all 168 net count data points, eliminating those above one 




           (2) 
where 
x = observed value 
𝜇 = mean of sample 
𝜎 = standard deviation of sample 
  
 A z-score was assigned since any net counts below zero show that the administering 
person did not have an uptake of iodine and had blocked the detector from any background 
radiation more effectively than the phantom had during the background count.  
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Lower Limit of Detection and Minimum Detectable Activity Determination 
The lower limit of detection (LLD) was calculated for background measurements using 
Equation 3 to show the threshold of radioactivity the detector could detect above background 
(Johnson 2017). 
 
LLD = (4.66 · σb) + 2.71        (3) 
where  
σb = standard deviation of the background 
 
Equation 3 can only be used if the background and sample counting times are equal. For 
the thyroid bioassay counts, the background and person are each counted for five minutes. 
 The minimum detectable activity (MDA) was calculated for each of the background 
measurements to show what activity in the administering person’s thyroid would be able to be 





         (4) 
where 
K = counter efficiency and a conversion to change transformation rate to Bq  
tg = sample and background counting time 
 
Maximum Level of Intake 
 The maximum level of intake that an administering person would have had was 
calculated using Equation 5, which is based on Equation 1.5 in NUREG 1400, to show whether a 
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maximum intake of I-131 by the administering person would have been detectable by the sodium 
iodide detector. 
 
 If = 
*	∙	,-"#
.%/
          (5) 
 where 
 If = predicted maximum likely intake as a fraction of the ALI 
 A = activity administered (Ci) 
 ALI = annual limit of intake for radionuclide from 10 CFR 20 Appendix B 
 
Decision Level Determination 
The decision level (LC) was then calculated for each background measurement using 
Equation 6 to determine if any of the samples required further investigation (ANSI HPS N13.30-
2011).  If the net counts exceed the LC, then further investigation is required. 
 
 LC = 2.33'𝑛/𝑟          (6) 
 where 
 n= the number of background counts 
 r = count rate 
 
Committed Dose Equivalent 
 The committed dose equivalent (CDE) was calculated for the bioassays that did show a 
positive result to show the dose to an administering person’s thyroid over 50 years based on the 
activity measurement of their thyroid during the bioassay. The CDE was calculated using 
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Equations 7 – 12 and assuming that the uptake was 0.3 of the intake, based on ICRP 30 (ICRP 
1979).  
 
𝐴 = 𝐴-𝑒"0)            (7) 
where 
A = activity measured at time of bioassay 
A0 = original activity  
𝜆 = decay constant of isotope 
t = time elapsed 
 
A0 ÷ 0.3 = I0           (8) 
where 
I0 = original intake 
 
𝐼- × 𝑆 = 	 ?̇?           (9) 
where 
S = MIRD table S value (rad/ µCi ∙ hr) 




(1 − 𝑒"0))          (10) 
where 
D = dose  
𝜆3 = effective half-life of isotope 
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t = 50 years 
 
𝐻4 = 𝐷 × 𝑤5           (11) 
where 
𝐻4 = equivalent dose to tissue due to radiation, R 
𝑤5 = radiation weighting factor 
 
R Software and RStudio Version 1.3.1073 were used to perform statistical tests on the 
data. The Shapiro-Wilks test for normality was used to calculate the normality of the distribution 
of net counts both with and without the counts that were more than one standard deviation below 
zero to determine if removing those points increased the normality of the distribution. A one 
sample two-sided t-test was used to see if the net counts were equally distributed around zero. A 
histogram was made to further validate the results of the t-test. Linear regression was used to 
show if there is a correlation between the net counts and the days elapsed between administration 
and the bioassay. A histogram was made for the residuals of the linear regression analysis to 
show if the regression line was accurately fit to the data. A second linear regression model was 
made to show if there is a correlation between the net counts and the amount of I-131 (mCi) 
administered. Another histogram was made for the residuals of the linear regression analysis to 
show if the regression line was accurately fit to the data. The activity measured in each person 







A z-score was calculated for all the net counts. The results can be found in Appendix E. 
12 of the net count data points had negative standard deviations greater than one, so the data 
points analyze decreased from 168 to 156.  
 
Lower Limit of Detection and Minimum Detectable Activity 
 The LLD was calculated to ascertain the threshold of counts the detector could 
distinguish above background. 101 background counts were analyzed due to the fact that not all 
of the bioassay reports included the background count; some only listed the overall net counts. 
The results are in Appendix F.  
The MDA, dependent on the LLD, was calculated for each background count to show the 
lowest detectable activity that the NaI(Tl) detector would be able to detect above background 
level with Type I and Type II error at 5%. The results are in Appendix F. The radiation control 
office (RCO) has set up the NaI(Tl) detector so that any measurements over 40 nCi would be 
assumed a positive detection, and based on the calculated MDAs, the greatest MDA is 3.32 nCi, 
so the detector would have been able to pick up any activity in the thyroid that the RCO has 
indicated would be a positive detection. 
 
Maximum Level of Intake 
 The maximum level of intake was calculated for the 101 I-131 administrations that 
included a background count in the bioassay to show the greatest amount of I-131 an 
 18 
administering person could have inhaled based on the amount of I-131 they administered to the 
cat. This amount was then compared to the MDA to confirm that the radioactivity would have 
been detected. The results are in Appendix F. The fraction of I-131 uptaken by the thyroid is 0.3 
of the intake, and based on the results in Appendix F, 101 are above the MDA.  
 
Decision Level Determination 
 The LC was not calculated by the RSO, but rather a value of 40 nCi was used 
operationally as the LC. The LC is used to determine if any samples would require further 
investigation of being a potential uptake, and assumes a Type I error of 5% and Type II error of 
50% . If the net counts of the sample exceed the LC, it is an indication that further investigation is 
required. The results from the calculation are in Appendix F. Based on the calculation, 11 
samples (highlighted in yellow) require further investigation.  
 
Committed Dose Equivalent 
 The CDE was calculated for any positive results from the bioassays so that the dose to an 
administering person’s thyroid over 50 years could be determined in the case that the uptakes 
were not false positives. Eight of the 168 bioassays showed a measurable activity, all of which 
measured 0.001 µCi. The measurements that showed a measurable activity were taken either 0 
days, 3 days, 7 days, 14 days, or 28 days post-administration. The calculated CDEs found were 
5.71 mrem (n=1), 7.53 mrem (n=2), 10.9 mrem (n=1), 20.7 mrem (n=1), and 75.1 mrem (n=2), 
respectively.  
 
Net Counts Normality 
 19 
The Shapiro-Wilks test for normality was performed on all 168 net count data points. The 
null hypothesis was that there is a normal distribution of net counts, and the alternative 
hypothesis was that there was a non-normal distribution of net counts. The p-value from the test 
was 2.2 × 10-16, which indicates that the null hypothesis is rejected, and the alternative 
hypothesis is accepted. A Normal Q-Q Plot of the net counts was also made and is shown below 
in Figure 4.  
 
 
Figure 4: Normal Q-Q Plot of all 168 net counts to show normality. 
  
A Normal Q-Q plot that shows a normal distribution of data should be completely linear 
with no curvature. Based on the Normal Q-Q plot in Figure 4, there is a lot of curvature, further 
validating the rejection of the null hypothesis. 
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A Z-score was calculated for all the net counts, and all negative net counts with a 
standard deviation greater than one were removed. This was done because negative net counts 
indicate that the background count was higher than the bioassay count, and so there could have 
been no uptake of radioiodine, and the administering person’s thyroid blocked the detector from 
the background more than the phantom. The Shapiro-Wilks test was reperformed after removal 
of the negative counts. The p-value greatly increased to 0.00049. While this still indicates that 
the null hypothesis is rejected, thus accepting the alternative hypothesis of a non-normal 
distribution of net counts, the normality of the data did increase with the elimination of the net 
counts that were less than one standard deviation below zero. A Normal Q-Q Plot was made and 
is shown in Figure 5. 
 
 
Figure 5: Normal Q-Q Plot of Net Counts with Elimination of Counts Greater than One Standard 
Deviation Below Zero. 
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The Normal Q-Q Plot of the log net counts much less curvature than the Normal Q-Q 
Plot shown in Figure 4, further validating the results from the Shapiro-Wilks test that the 
normality of the net counts did increase when they were log transformed. 
 
Net Counts Distribution 
 168 net counts were then analyzed using a one-sample two-sided t-test to determine if 
there was an equal distribution above and below zero. The p-value given by the test was 5.8 × 
10-5. The histogram of the net counts is in Figure 6.   
 
 
Figure 6: Histogram of All Net Counts to Show Distribution. 
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The null hypothesis was that there would be an equal distribution of net counts above and 
below zero. The alternative hypothesis was the mean of the net counts would not be equally 
distributed around zero. Based on the p-value, the null hypothesis was rejected, and the 
alternative hypothesis was accepted. In viewing the histogram, it can be visually concluded that 
there is a disproportional distribution of net counts below zero in comparison to those above 
zero, though the distribution immediately around zero is normal. 
The net counts below zero indicate that the background had a higher amount of detectable 
radiation than the administering person’s thyroid, leading to the conclusion that the person did 
not have an uptake of radioiodine. For this reason, the net counts greater than one standard 
deviation below zero were removed and the distribution of net counts around zero was analyzed 
again. The p-value greatly increased to 0.0095, and though this value still indicates that we reject 
the null hypothesis of an equal distribution around zero and conclude that it is not equally 
distributed, it does show that there was a great increase equality of distribution. This can also be 




Figure 7: Histogram of Net Counts with Elimination of Counts Greater than One Standard 
Deviation Below Zero. 
 
Linear Regression of Net Counts and the Time Elapsed Between Administration and the 
Bioassay  
Linear regression was used to check for a correlation between the time elapsed between 
168 administrations and bioassays and the net counts corresponding to each administration. The 
red dots on the model indicate the approximate location of the bioassays that showed a positive 
activity. The null hypothesis was that there was no correlation between the number of days 
elapsed and the net counts, and the alternative hypothesis was that there was a correlation. The p-
value obtained was 0.82, indicating a failure to reject the null hypothesis. The linear regression 
model is shown below in Figure 8.  
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Figure 8: Linear Regression Model of All Net Counts vs Days Elapsed Between Administration 
and Bioassay. 
 
To further validate the linear regression analysis, a histogram of the residuals was made 
to show if the line fit the data set well. A residual is the distance between each data point being 
analyzed and the regression line. Residuals should have a normal distribution in order for the 
conclusions drawn from the regression analysis to be valid. The histogram of residuals from the 
linear regression analysis of all the net counts and the days elapsed between I-131 administration 




Figure 9: Histogram of Residuals from Linear Regression Model of All Net Counts vs Days 
Elapsed Between Administration and Bioassay. 
 
Based on Figure 9, the residuals are not normally distributed, which shows an 
invalidation of the linear regression analysis of all the net counts. 
When the negative net counts with a standard deviation greater than one were eliminated, 
the p-value decreased slightly to 0.22, but this value still indicates that the null hypothesis is 
rejected and we conclude that there is no correlation between the days elapsed between 
administration and bioassay and the net counts from each bioassay. The linear regression model 





Figure 10: Linear Regression Model of Net Counts with Elimination of Counts Greater than One 
Standard Deviation Below Zero vs Days Elapsed Between Administration and Bioassay. 
 
Based on the linear regression model, there is a slight positive correlation between the net 
counts with the elimination of the counts more than one standard deviation below zero and the 
amount of time elapsed between administration and bioassay, but because of the p-value, the 
positive slope must therefore be slight enough that it does not indicate a true correlation. A 
histogram of the residuals from this plot was made to indicate whether or not the linear 




Figure 11: Histogram of Residuals from Linear Regression Model of Net Counts with 
Elimination of Counts Greater than One Standard Deviation Below Zero vs Days Elapsed 
Between Administration and Bioassay. 
  
 Based on the histogram of residuals in Figure 11, they have a much more normal 
distribution and therefore the linear regression analysis of the net counts without the points 
greater than one standard deviation below zero is validated. 
 
Linear Regression of Net Counts and Amount of I-131 (mCi) Administered 
Linear regression was used to check for a correlation between 168 values of amounts of 
I-131 administered the net counts corresponding to each administration. The null hypothesis was 
that there was no correlation between the amount of I-131 administered and the net counts, and 
the alternative hypothesis was that there was a correlation. The p-value obtained was 0.72, 
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indicating a failure to reject the null hypothesis. The linear regression model is below in Figure 
12, and the red dots indicate the approximate locations of the positive bioassays.  
 
Figure 12: Linear Regression Model of All Net Counts and Amount of I-131 Administered. 
 
Based on the linear regression model in Figure 12, there appears to be no correlation 
between the amount of I-131 administered and the net counts, further validating conclusion 
drawn from the p-value. A histogram of the residuals from this linear regression analysis was 




Figure 13: Histogram of Residuals from Linear Regression Model of All Net Counts and 
Amount of I-131 Administered. 
 
Based on the histogram in Figure 13, the residuals are not normally distributed, and 
therefore the conclusion drawn from the linear regression analysis of all the net counts and the 
amount of I-131 administered cannot be validated. 
When the negative net counts with a standard deviation greater than one were eliminated, 
the p-value increased slightly to 0.95, indicating that the null hypothesis is rejected and 
concluding that there is no correlation between the days elapsed between administration and 
bioassay and the net counts from each bioassay. A linear regression model was made and is 
below in Figure 14, and the red dots indicate the approximate locations of the positive bioassays. 
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Figure 14: Linear Regression Model of Net Counts with Elimination of Counts Greater than One 
Standard Deviation Below Zero vs Amount of I-131 Administered. 
  
Based on the linear regression model plot, there is no correlation between the log of the 
net counts and the amount of I-131 administered, further validating the conclusion drawn from 
the p-value. A histogram of the residuals from this linear regression analysis was made to 




Figure 15: Histogram of Residuals from Linear Regression Model of Net Counts with 
Elimination of Counts Greater than One Standard Deviation Below Zero vs Amount of I-131 
Administered. 
   
 Based on Figure 15, the residuals are normally distributed and therefore the conclusion 
drawn from the linear regression analysis of the net counts without the counts greater than one 







 A z-score was calculated for all the net counts, days elapsed between I-131 
administration and bioassay, and amounts of I-131 administered, and data points more than three 
standard deviations away from the mean were eliminated. The removal of these data points 
caused an increase in the normality of the data.  
 Net count outliers could have been caused for a variety of reasons, such as a higher or 
lower radon background on the day of counting or the body of the administering person shielding 
the detector from background activity more than the phantom.  
 
Lower Limit of Detection and Minimum Detectable Activity 
 The LLD was calculated for all the background counts to show the minimum amount of 
counts that would have been detected above background level. Determining the LLD allowed for 
the MDA to be calculated. The lowest MDA was 0.00126 µCi, which corresponds to when the 
detector was able to detect the lowest amount of activity above background level. It is four 
orders of magnitude below the NALI of 50 µCi. The lowest recorded activity in an administering 
person’s thyroid was 0.001 µCi, which shows that the detector was sensitive enough to detect 
even low amounts of I-131 in the person’s thyroid. 
 
Maximum Level of Intake 
 The maximum level of intake of I-131 was calculated so that the greatest amount of I-131 
an administering person could have inhaled could be determined, allowing for the maximum 
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uptake of I-131 by the thyroid to be calculated and compared against the MDA. A maximum 
intake of I-131 would have only occurred if the regulations regarding the administration of I-131 
were completely disregarded by the administering person. Based on the activity measurements of 
the administering persons’ thyroids in Appendix F, none came close to the maximum uptake, 
validating the effectiveness of the precautions taken by the administering persons at CSU VTH.  
 
Decision Level Determination 
 The LC was calculated so that potential false positives could be identified and 
investigated further. The calculation showed that 11 bioassay counts could have indicated a false 
positive. Due to the fact that the bioassay records span the past 20 years and the effective half-
life of I-131 is 7.5 days, it would not be possible to go back and investigate the bioassays that 
were indicated to be potential false positives.  
 
Committed Dose Equivalent 
 The CDE of the 7 bioassays which showed a measurable activity were at least 4 orders of 
magnitude below the intake regulatory limit of 10 rem set by the Regulatory Guide 8.20 and the 
NALI of 50 rem. Based on these results, assuming that the activity measurements were not false 
positives, over the 20 year span of the bioassay records, uptakes of I-131 by administering 
persons have been at least three orders of magnitude below regulatory limits.   
 
Net Counts Normality 
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The analysis from the Shapiro-Wilks test of the 168 net count data points showed that 
there was still a lack of normality in the distribution of the net counts. The Normal Q-Q Plot of 
this data set further validated the Shapiro-Wilks test. 
The analysis from the Shapiro-Wilks test of the 156 net count data points that excluded 
those greater than one standard deviation below zero showed that, while there was still a lack of 
normality, the normality did greatly increase. The linearity of the Normal Q-Q Plot also 
increased, further validating the Shapiro-Wilks test. 
It was reasonable to remove the net counts greater than one standard deviation below zero 
because they indicated that the background count was higher than the bioassay count. Most 
likely the administering person blocked the NaI(Tl) detector from the background radiation more 
effectively than the phantom, causing the net counts to be negative. Based on the negative net 
counts, the administering person could not have had an uptake of radioiodine. 
The lack of normality of net counts could be attributed to many different factors, such as 
background fluctuations, radon being present naturally in higher or lower quantities in the air on 
the day of the bioassay, the amount of I-131 that actually interacted with the NaI(Tl) detector 
that day, or the random nature of radioactive decay. The bioassay data used spanned over 20 
years, so there is a great amount of variability in background over such an expanse of time.   
 
Net Counts Distribution 
 The analysis of the mean of the 168 net counts indicated that the distribution falls below 
zero, meaning that overall the bioassays indicated that the administering persons had a lower I-
131 count than the background measurement. This could happen for multiple reasons, one being 
the random nature of radioactive decay. Another reason could be that although an 
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anthropomorphic phantom was in the place of a human while the background was being counted, 
the actual person being counted was able to block more radiation from reaching the NaI(Tl) 
detector than the phantom. This can be seen in the histogram depicted in Figure 6. After the net 
counts more than one standard deviation below zero were removed, the distribution of counts 
around zero greatly increases in equality, as can be seen in Figure 7. 
 
Linear Regression Model of Log of the Net Counts and the Time Elapsed Between 
Administration and the Bioassay  
The linear regression model of the net count data demonstrated no correlation between 
the net counts and the time elapsed between I-131 administration and the bioassay, based on the 
p-value. The analysis of the residuals, however, indicated that these findings were invalidated 
due to the non-normal distribution of residuals. The linear regression model of the net counts 
without those greater than one standard deviation below zero demonstrated a slight positive trend 
between the net counts and the time elapsed between I-131 administration and the bioassay, but 
the p-value demonstrated that there was no statistical correlation. This was further validated by 
the analysis of the residuals, which showed a normal distribution. Due to the lack of correlation 
from this linear regression model, if an administering person waited longer than the guidelines of 
24-72 hours, they would not necessarily have a higher or lower net count than a person who had 
a bioassay done within that timeframe, even though the effective half-life of I-131 is 7.5 days.  
One area for concern with the conclusion drawn from this data is that there is a 
disproportionate number of bioassays from up to two weeks post-administration versus bioassays 
performed greater than two weeks post-administration. This causes a skew in the data set that can 
be seen in Figures 8 and 9. If this had been a controlled experiment rather than using historical 
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data, the bioassays could be performed with the same amount of I-131 administered but different 
lengths of time between the administration and the bioassay, aiding in removing variables and 
improving the skew of the data, thus making it easier to ascertain any existing trends. 
 
Linear Regression Model of Log of the Net Counts and the Time Elapsed Between 
Administration and the Bioassay  
The linear regression model of the net count data indicated that there would be no 
correlation between the net counts and the amount of I-131 administered, and the p-value further 
demonstrated no statistical correlation. This conclusion, however, was invalidated by the analysis 
of the residuals, which showed a non-normal distribution. The linear regression model of the net 
counts without those greater than one standard deviation below zero also indicated there would 
be no correlation between the net counts and the amount of I-131 administered, and the p-value 
further demonstrated that there was no correlation. This conclusion was validated by the analysis 
of the residuals, which showed a normal distribution. Based on the lack of correlation from this 
model, it is demonstrated that the amount of I-131 administered does not influence the net counts 
of the administering person. If a person administers a great amount of I-131, they would not 
necessarily have a higher net count than someone who administered less I-131.  
One area for concern with the conclusion drawn from this data is that there is a 
disproportionate number of bioassays taken from people who administered 20 µCi of I-131 or 
less versus bioassays from people who administered more than 20 µCi. This causes a skew in the 
data set that can be seen in Figures 10 and 11. If this had been a controlled experiment rather 
than using historical data, the bioassays could be performed with different amounts of I-131 
administered but the same length of time between the administration and the bioassay, aiding in 
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removing variables and improving the skew of the data, thus making it easier to ascertain any 
existing trends. 
 
Analysis of Activity Measured in Administering Person 
 Of the 168 data points, 7 bioassays indicated an activity that was measured above 0 µCi. 
No statistical tests could be performed to ascertain the activity deposited in each administering 
person due to the lack of activity measured in the bioassays. The highest activity recorded in the 
bioassays was 0.001 µCi, which would indicate an inhalation of 0.003 µCi, and is 4 orders of 
magnitude smaller than the NALI of 50 µCi. Considering that these bioassays come from 32 
different administering persons over a span of 20 years, it is remarkable that only 7 bioassays 
had measurable uptakes.  
 
Future Studies 
 While this project was designed specifically for the CSU VTH, it would be worthwhile to 
review bioassays from other veterinary hospitals with the capability of administering I-131 to 
examine trends between the amount of I-131 administered, time elapsed between administration 
and bioassay, and net counts. Since this study dealt with historical data, there were some skews 
in the data that may have influenced the results. It would be beneficial to do a standardized study 
where only one variable is changed at a time and re-perform the statistical tests to check for 
trends in the data. It would also be useful to see if all uptakes lie within the parameters of the LC. 
There is a lack of literature on studies of the effective protection of I-131 administering persons. 
If there are variations between veterinary hospitals in iodine uptakes, then training programs 
from the successful hospitals could be implemented at those that have been less successful with 
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protecting their staff. Reviewing all of this information could also be beneficial for hospitals that 
administer I-131 to treat human patients. Similar studies could also be used for other nuclear 










 The use of I-131 to treat cats with thyroid tumors has been proven to be a highly effective 
method of treatment, but with that procedure comes the potential risk of unnecessarily exposing 
the administering veterinarian or veterinary technician to I-131, which could potentially be 
harmful. All people who will be handling the I-131 and treated the animals are required to be 
trained in proper handling of radioactive materials and animals. Guidelines are also in place to 
regulate how often and under what circumstances bioassays are necessary for the administering 
person. While bioassays can be extremely useful in alerting a worker if they have had an uptake, 
the administering persons work in a predictable environment, performing the same procedure 
and taking the same precautions each time. If the procedure is properly followed for each 
administration, there should be no risk of uptake of I-131. 
 It was shown through the calculation of the MDA that the NaI(Tl) detector would have 
been able to detect a positive bioassay during all of the measurements taken. The maximum level 
of I-131 that could have been uptaken by the thyroid was always above the MDA, so any activity 
in the thyroid should have been detected. While the calculation of the LC indicated that 11 
bioassays could have been false positives, only 7 bioassay results indicated an activity above 
background level. The CDEs of the activities in these bioassays were all at least 4 orders of 
magnitude below both the regulatory limit of intake set by Regulatory Guide 8.20 and the NALI.  
 It was hypothesized that there would be a negative correlation between the time elapsed 
between I-131 administration and the bioassay and the net counts resulting from the bioassay. It 
was also hypothesized that there would be a positive correlation between the amount of I-131 
administered and the net counts resulting from the bioassay. After reviewing 20 years worth of 
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data of 168 total bioassays from 32 administering persons, no correlations could be identified 
between the net counts and amount of time elapsed between the administration and the bioassay. 
No correlation could also be found between the net counts and the amount of I-131 administered. 
The current guidelines that CSU VTH must follow from CDPHE and Regulatory Guide 8.20 
state that bioassays are required after administration of I-131, however, this data shows that the 
training procedures for I-131 administration at CSU VTH are sufficient to protect the 
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 Decay scheme of I-1315. 
 
 







Based on ICRP 30, 30% of an intake of iodine is uptaken by the thyroid.  Based on the 
values in 10 CFR 20 Appendix B, the NALI of I-131 is equal to 50 rems in the thyroid, which is 
equivalent to 50 µCi. Reaching 10% of the NALI would mean an intake of 5 rems, or 5 µCi, and 
an intake of 1.67 µCi. The counting efficiency of NaI(Tl) detector used to conduct the bioassays 
is 0.17%, and the average background reading is 31.09 cpm.  
 
Decays per minute in the thyroid 
 
1.67	µCi ∙ 1	Ci1	 ×	106	µCi ∙ 3.7	 × 	10
,-dps1	Ci ∙ 60	s1	min = 3.7 × 106	dpm 
 
Effective half-life of I-131 
 8.05	d × 120	d8.05	d + 120	d = 7.5	d	 
 
Decay constant of I-131 in the thyroid 
 ln(2)7.5 = 0.092 = 𝜆 
 
Decays per minute of the background 
 0.17100 × 31.09	cpmdpm = 18288.24	dpm 
 
Standard deviation of the background 
 
P31.09	cpm5	min = 2.49	cpm 
 
Decays per minute of standard deviation of the background 




 2.33 × 1464.71 = 3412.76	dpm 
 
Lowest background reading above decision level 
 18288.24 + 3412.76 = 21701.00	dpm 
 
Length of time for I-131 activity in thyroid to reach background counts 








Based on ICRP 30, 30% of an intake of iodine is uptaken by the thyroid. Regulatory 
Guide 8.20 has set the intake limit as 10 mCi, which is 20% of the NALI, meaning an uptake of 
3.33 mCi of I-131. The counting efficiency of NaI(Tl) detector used to conduct the bioassays is 
0.17%, and the average background reading is 31.09 cpm.  
 
 
Decays per minute in the thyroid 
 
3.33	mCi ∙ 1	Ci1	 ×	10:	µCi ∙ 3.7	 × 	10
,-dps1	Ci ∙ 60	s1	min = 7.4 × 108	dpm 
 
Effective half-life of I-131 
 8.05	d × 120	d8.05	d + 120	d = 7.5	d	 
 
Decay constant of I-131 in the thyroid 
 ln(2)7.5 = 0.092 = 𝜆 
 
Decays per minute of the background 
 0.17100 × 31.09	cpmdpm = 18288.24	dpm 
 
Standard deviation of the background 
 
P31.09	cpm5	min = 2.49	cpm 
 
Decays per minute of standard deviation of the background 




 2.33 × 1464.71 = 3412.76	dpm 
 
Lowest background reading above decision level 
 18288.24 + 3412.76 = 21701.00	dpm 
 
Length of time for I-131 activity in thyroid to reach background counts 




























































































































































































































































Table 2: Total background counts, lower limit of detection, minimum detectable activity, 















31.4 17.6 0.00154 0.0 0.0 5.84 -10.00 
28.6 16.9 0.00148 90.0 27.0 5.57 -5.40 
26.8 16.5 0.00144 80.0 24.0 5.39 1.40 
27.6 16.7 0.00146 80.0 24.0 5.47 1.80 
26.8 16.5 0.00144 600.0 180.0 5.39 -2.80 
30 17.3 0.00151 600.0 180.0 5.71 -4.20 
24 15.7 0.00137 0.0 0.0 5.10 1.00 
19.8 14.5 0.00126 0.0 0.0 4.64 4.00 
25.8 16.2 0.00141 120.0 36.0 5.29 -0.20 
25.6 16.2 0.00141 1760.0 528.0 5.27 -1.40 
21 14.9 0.00129 1760.0 528.0 4.78 1.80 
22 15.2 0.00132 88.0 26.4 4.89 10.60 
28 16.8 0.00147 1200.0 360.0 5.51 -0.40 
22 15.2 0.00132 64.0 19.2 4.89 -0.20 
20.8 14.8 0.00129 54.0 16.2 4.75 -5.60 
21.8 15.1 0.00131 600.0 180.0 4.87 -2.40 
22.6 15.4 0.00133 45.0 13.5 4.95 -0.20 
23.8 15.7 0.00136 80.0 24.0 5.08 -4.60 
20.6 14.8 0.00128 56.0 16.8 4.73 0.80 
25.2 16.1 0.00140 80.0 24.0 5.23 -6.00 
25.2 16.1 0.00140 80.0 24.0 5.23 3.60 
24.6 15.9 0.00138 0.0 0.0 5.17 -6.00 
28.2 16.8 0.00147 1600.0 480.0 5.53 -1.80 
22.4 15.3 0.00133 50.0 15.0 4.93 -3.20 
27.4 16.6 0.00145 90.0 27.0 5.45 -0.80 
40.8 19.7 0.00174 90.0 27.0 6.66 -15.00 
21.8 15.1 0.00131 60.0 18.0 4.87 7.60 
24.2 15.8 0.00137 60.0 18.0 5.13 3.00 
22.2 15.2 0.00132 80.0 24.0 4.91 -1.20 
















25.6 16.2 0.00141 1760.0 528.0 5.27 -6.40 
21 14.9 0.00129 1760.0 528.0 4.78 0.60 
24.4 15.8 0.00138 2000.0 600.0 5.15 2.40 
26.6 16.4 0.00143 0.0 0.0 5.37 3.20 
25.8 16.2 0.00141 120.0 36.0 5.29 1.80 
67.2 24.5 0.00218 90.0 27.0 8.54 -35.00 
27.4 16.6 0.00145 85.0 25.5 5.45 10.20 
74 25.6 0.00228 240.0 72.0 8.96 -37.00 
86.8 27.5 0.00246 160.0 48.0 9.71 -35.20 
164 36.8 0.00332 900.0 270.0 13.34 -70.80 
71 25.1 0.00224 92.0 27.6 8.78 -36.00 
60.09 23.3 0.00207 80.0 24.0 8.08 -19.69 
67.2 24.5 0.00218 90.0 27.0 8.54 -37.40 
42 19.9 0.00176 80.0 24.0 6.75 -9.20 
34 18.2 0.00160 82.2 24.7 6.08 -2.60 
72.8 25.4 0.00227 80.0 24.0 8.89 -15.40 
26.8 16.5 0.00144 175.0 52.5 5.39 0.00 
31.6 17.7 0.00155 84.0 25.2 5.86 -8.20 
35.6 18.6 0.00163 80.0 24.0 6.22 -9.40 
31.4 17.6 0.00154 89.0 26.7 5.84 -3.40 
28.6 16.9 0.00148 90.0 27.0 5.57 1.60 
23 15.5 0.00134 90.0 27.0 5.00 5.40 
25 16.0 0.00139 80.0 24.0 5.21 0.60 
26.2 16.3 0.00142 90.0 27.0 5.33 0.00 
21.8 15.1 0.00131 70.0 21.0 4.87 10.20 
24 15.7 0.00137 160.0 48.0 5.10 4.60 
27.6 16.7 0.00146 80.0 24.0 5.47 7.00 
29.4 17.1 0.00150 80.0 24.0 5.65 3.00 
24.4 15.8 0.00138 600.0 180.0 5.15 7.40 
26.8 16.5 0.00144 80.0 24.0 5.39 -6.40 
30 17.3 0.00151 80.0 24.0 5.71 -1.20 
24.2 15.8 0.00137 40.0 12.0 5.13 8.80 
27.8 16.7 0.00146 40.0 12.0 5.49 6.00 
21.8 15.1 0.00131 0.0 0.0 4.87 1.60 
















22.8 15.4 0.00134 80.0 24.0 4.98 4.00 
25 16.0 0.00139 250.0 75.0 5.21 -1.80 
27.8 16.7 0.00146 0.0 0.0 5.49 -2.40 
67.8 24.6 0.00219 86.0 25.8 8.58 -43.80 
29.4 17.1 0.00150 60.0 18.0 5.65 -6.80 
24.2 15.8 0.00137 80.0 24.0 5.13 3.40 
24.4 15.8 0.00138 0.0 0.0 5.15 0.00 
65.8 24.3 0.00216 180.0 54.0 8.45 -36.20 
63.8 24.0 0.00213 90.0 27.0 8.32 -20.40 
40.8 19.7 0.00174 160.0 48.0 6.66 -16.20 
39.6 19.4 0.00171 80.0 24.0 6.56 -10.20 
35.8 18.6 0.00164 160.0 48.0 6.23 -9.20 
24 15.7 0.00137 89.0 26.7 5.10 1.20 
31.4 17.6 0.00154 86.0 25.8 5.84 -11.80 
23 15.5 0.00134 80.0 24.0 5.00 -0.40 
26.2 16.3 0.00142 89.4 26.8 5.33 1.80 
29.4 17.1 0.00150 86.0 25.8 5.65 -4.20 
21.8 15.1 0.00131 0.0 0.0 4.87 2.40 
26.2 16.3 0.00142 93.4 28.0 5.33 8.80 
54 22.3 0.00197 186.0 55.8 7.66 -23.80 
60.09 23.3 0.00207 80.0 24.0 8.08 -26.24 
39 19.3 0.00170 102.0 30.6 6.51 -13.00 
34.8 18.4 0.00162 102.0 30.6 6.15 -11.40 
26.8 16.5 0.00144 175.0 52.5 5.39 -4.80 
34 18.2 0.00160 82.2 24.7 6.08 -8.80 
72.8 25.4 0.00227 80.0 24.0 8.89 -6.80 
26.2 16.3 0.00142 93.4 28.0 5.33 9.80 
54 22.3 0.00197 84.0 25.2 7.66 -23.20 
39 19.3 0.00170 102.0 30.6 6.51 -16.20 
34.8 18.4 0.00162 102.0 30.6 6.15 -10.80 
31.6 17.7 0.00155 84.0 25.2 5.86 -7.80 
34 18.2 0.00160 0.0 0.0 6.08 -11.60 
24.97 16.0 0.00139 0.0 0.0 5.21 -4.58 
20.2 14.7 0.00127 120.0 36.0 4.68 -0.60 
















90.6 28.0 0.00251 380.0 114.0 9.92 -33.80 
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As low as reasonably achievable 
Committed Dose Equivalent 
Colorado Department of Health and the Environment 
Colorado State University 
Double stranded break 
Decision level 
Lower limit of detection 
Nonstochastic limit of intake 
Predetermined action level 
Personal protective equipment 
Safety data sheet 
Single stranded break 
Radiation Control Office 
Radiation Safety Officer 
Veterinary Teaching Hospital 
 
